tiprankstipranks
Monopar Therapeutics Reports Positive MNPR-101-Zr Trial Results
Company Announcements

Monopar Therapeutics Reports Positive MNPR-101-Zr Trial Results

Don't Miss Our Christmas Offers:

Monopar Therapeutics Inc ( (MNPR) ) has shared an update.

Monopar Therapeutics Inc. announced promising early results from its MNPR-101-Zr Phase 1 clinical trial, showcasing the compound’s ability to specifically target tumors in cancer patients. The trial’s positive outcomes, based on PET imaging, validate the targeted approach of MNPR-101-Zr, a humanized monoclonal antibody, against cancers with high expression of the urokinase plasminogen activator receptor, such as triple-negative breast, colorectal, and pancreatic cancers. These findings pave the way for future therapeutic developments, with additional data set to be presented at a prestigious medical congress.

See more data about MNPR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyMonopar Therapeutics prices 798,655 shares at $23.79 in registered offering
TipRanks Auto-Generated NewsdeskMonopar Therapeutics Achieves Milestone in Cancer Treatment
TheFlyMonopar Therapeutics doses first patient with MNPR-101-Lu
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App